About PMGC Holdings Inc
- Industry: Consumer products
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://pmgcholdings.com/
Frequently Asked Questions
What is the 52-week range for ELAB?
The 52-week high is $2671.2 and the 52-week low is $2.585.
What is the P/E ratio for ELAB?
The P/E ratio data is currently unavailable.
What is the dividend yield for ELAB?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -118.11%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -522.96%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.14.
Latest ELAB News
PMGC Holdings (Nasdaq: ELAB) Announces Completion of $100 Million SPAC IPO, Launching NorthStrive Acquisition Corp. I (Nasdaq: NSAI) as First in Planned SPAC Sponsorship Franchise to Expand M&A Strategy
PMGC's first sponsored SPAC adds a public-market acquisition vehicle to the holding company, targeting aerospace and defense, industrial technology, and critical supply chain manufacturersSponsor position of approximately 2.7 million shares, or roughly 21.4% of NorthStrive Acquisition Corp I.'s Class A shares on an as-converted basis, aligns PMGC with value created through a future business combination NEWPORT BEACH, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“P
NorthStrive Biosciences Partners with Charles River Laboratories to Advance Its EL-22 and EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive Biosciences’ expanding manufacturing and characterization capabilities behind its engineered probiotic platform targeting muscle preservation, including for patients on GLP-1 weight loss treatments NEWPORT BEACH, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq:
PMGC Holdings’ Northstrive Biosciences Executes Statement Of Work With Charles River To Conduct Analytical Characterization Supporting Development Of EL-22 And EL-32 Engineered Probiotic Programs
Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development frameworkBuilds on NorthStrive
PMGC Holdings Inc. (Nasdaq: ELAB) Secures Five-Year Royalty Stream from Elevai Skincare Sale Under Executed Payment Agreement with Longevity Health Holdings
Binding, interest-bearing payment plan converts PMGC’s 5% net sales royalty into scheduled monthly cash payments to NorthStrive Biosciences through August 2031, creating recurring, non-dilutive cash flowAgreement covers the 2025 royalty and all future royalty and earnout payments, backed by joint and several obligors, mandatory prepayments tied to Longevity capital events, and annual audit rights NEWPORT BEACH, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (“PMGC” or the “Company
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-01 | Bensler Graydon | +450,277 | - | - |
| 2026-06-01 | Parry Jeffrey | +75,046 | - | - |
| 2026-06-01 | Kovalyov George | +75,046 | - | - |
| 2026-06-01 | Braeden Lichti | +450,277 | - | - |
| 2026-06-01 | Daley Juliana | +75,046 | - | - |